Introduction
Elevated blood pressure (BP) increases the risk for stroke, myocardial infarction (MI), heart failure and kidney disease. 1 Despite targeted public health efforts to prevent hypertension, more than one quarter of the US and Canadian adult population has elevated systolic and/or diastolic BP and/or is taking antihypertensive medication. In -2004 , the overall prevalence of hypertension in the United States was 29.3%, with the highest prevalence (66.3%) among persons aged 60 years and older. The overall prevalence of hypertension in Europe seems to be even higher (38-55%). [2] [3] [4] A recent analysis and commentary direct attention to the impact of hypertension outside western, industrialized nations. Researchers found that BP-related diseases cause approximately 8 million deaths every year, with about 80% of the cardiovascular disease (CVD) burden occurring in low-income and middleincome countries. 5, 6 The disease burden of hypertension is likely to increase in the coming decades. 3 In the United States, the prevalence of hypertension has increased by approximately 3.7% since the late 1980s. 3 Despite recent modest improvements, 2, 7, 8 generally BP control rates are low, and, in particular, remain suboptimal among patients with the highest risk for CVD, including the elderly and persons with severe hypertension. In [2003] [2004] in the United States, the age-adjusted control rate among treated hypertensive patients was 63.9%, and the control rate among treated hypertensive patients with diabetes was only 33.2%. Control rates in Europe are also low. 1, 2, 4, 7 Hypertension is the most important modifiable risk factor associated with premature cardiovascular morbidity and mortality. 9 The benefit of pharmacologic treatment of hypertension in reducing CVD morbidity and mortality is well established, 8, 10, 11 with tighter BP control conferring greater risk reduction. 10, 12, 13 The majority of patients with hypertension require treatment with two or more antihypertensive medications to reach the target BP. Lack of adherence with prescribed treatment is one of the most important factors that may affect BP control. 1, 14 Inhibitors of the renin-angiotensin system (RAS)-angiotensin-II receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors (ACEIs)-and long-acting dihydropyridine calcium channel blockers (DHP-CCBs) have excellent efficacy and safety profiles, and may provide particular benefits in patients with certain high-risk conditions, including previous CVD, albuminuria, left ventricular hypertrophy (LVH), diabetes mellitus and chronic kidney disease. 1, [15] [16] [17] [18] Moreover, these newer classes of antihypertensive drugs provide CVD benefits comparable, and possibly superior, to other classes of agents. 18, 19 Combination treatment appears to offer a number of advantages over higher doses of single agents, including better BP control and improved tolerability and adherence. 20 This article presents an overview of RAS blocker and CCB outcome trials and the rationale for the use of RAS blocker/DHP-CCB combination therapy to reduce global cardiovascular risk in patients with hypertension.
A Medline search was conducted to identify studies published between January 2001 and May 2007 that evaluated the effects of RAS inhibitors and DHP-CCBs, as well as combination therapy with those classes of agents, on clinical outcomes. The following search terms were used: 'angiotensinconverting enzyme inhibitor', 'angiotensin II receptor blocker', 'calcium channel blocker', 'dihydropyridine calcium channel blocker', 'combination therapy', 'antihypertensive therapy', 'cardiovascular', 'risk reduction' and 'clinical trials.' Major treatment guidelines were reviewed for relevant clinical trials that may not have been captured by this search strategy. Mentioning all the studies identified, however, is beyond the scope of this review.
Reducing cardiovascular risk with RAS inhibitors and CCBs
In addition to its role in regulating BP, RAS is involved in altering the process of structural adaptation of the heart, thereby contributing to the development of LVH, heart failure and renal disease in patients with hypertension ( Figure 1) . [21] [22] [23] The two most established classes of RAS blockers, ACEIs and ARBs, are effective antihypertensive agents and are widely used to treat hypertensive target organ damage. 1, 21, 22 Evidence from mega-trials of ACEIs Large, randomized, controlled trials have confirmed that ACEIs are as effective and safe as diuretics and reduce the risk of cardiovascular morbidity and mortality. [24] [25] [26] [27] [28] [29] In the Captopril Primary Prevention Project (CAPPP), for example, 10 985 patients aged 25-66 years with diastolic BP X100 mm Hg were treated with the ACEI captopril or conventional therapy (diuretic or b-blocker) for a mean of 6.1 years. 26 The reduction in risk of the primary outcome measure (combined cardiovascular deaths, fatal and nonfatal MI, fatal and nonfatal stroke) was similar between treatment groups. 30 In the Heart Outcomes Prevention Evaluation (HOPE), 9297 patients aged X55 years with a history of coronary artery disease, stroke, peripheral vascular disease or diabetes plus at least one additional cardiovascular risk factor were treated with ramipril or placebo for 4 years. 27 Ramipril treatment was associated with a 22% reduction in risk of combined MI, stroke and cardiovascular mortality (relative risk, 0.78; 95% confidence interval (CI), 0.70-0.86; Po0.001), an effect that, to some extent, was independent of BP lowering. The benefits of ACEIs have also been evaluated and confirmed in specific subgroups of patients, including patients with previous stroke or transient ischaemic attack in the Perindopril Protection against Recurrent Stroke Study (PROGRESS) 28 and elderly patients in the Second Australian National Blood Pressure Study. 29 Evidence from ARB mega-trials Mega-trials of ARBs in patients with hypertension have confirmed that BP control with these agents reduces CVD morbidity and mortality in a range of patients, including those with diabetes mellitus, heart failure or LVH, and those at risk of developing heart failure following an MI. 31 In the double-blind, randomized Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, more than 9000 patients with treated or untreated hypertension (mean baseline BP 174/98 mm Hg) and electrocardiographically documented LVH were assigned losartan-or atenolol-based therapy, with doses increased from 50 to 100 mg and other agents added, as necessary, to achieve a target BP of o140/90 mm Hg. 18 After a mean of almost 5 years of follow-up, BP fell by 30/17 mm Hg in the losartan group and 29/17 mm Hg in the atenolol group; at the Angiotensin II concentration Figure 1 Left ventricular mass in never-treated patients according to angiotensin II concentrations in relation to urinary sodium excretion. Reprinted with permission from Schmieder RE et al.
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RAS/CCB combination therapy B Dahlöf end of the study, a majority of patients in both arms were on added hydrochlorothiazide and almost half on added DHP-CCB. 18 Equivalent proportions of patients reached the target BP (49 and 46%, respectively, for the systolic target and 89% in both groups for the diastolic target). 18 The mean arterial pressure at follow-up was similar in both treatment groups.
The primary composite end point of cardiovascular death, MI or stroke was reduced by 13% with losartan-compared with atenolol-based treatment (hazard ratio ¼ 0.87; 95% CI, 0.77-0.98; P ¼ 0.021), primarily as a result of a significant 25% reduction in fatal or nonfatal stroke (95% CI, 11-37%; P ¼ 0.001) (Figure 2 ). 18 Losartan-based therapy reduced the rate of new-onset atrial fibrillation by 33% compared with atenolol-based therapy (relative risk 0.67; 95% CI, 0.55-0.83; Po0.001) despite similar BP reduction. 32 The development of newonset diabetes was also reduced significantly with losartan-based therapy. In the subgroup of patients with diabetes at baseline (n ¼ 1195), losartan significantly decreased the primary composite end point relative to atenolol by 24% (95% CI, 2-42%; P ¼ 0.031), primarily owing to a significant 37% reduction in cardiovascular mortality (95% CI, 5-58%; P ¼ 0.028). 33 The large-scale (n415 000), prospective Valsartan Antihypertensive Long-term Use Evaluation (VA-LUE) study was also designed to attain a target BP of o140/90 mm Hg, but, in this case, with valsartanbased (80-160 mg) or amlodipine-based (5-10 mg) therapy. 34 At baseline, the mean BP was approximately 154/87 mm Hg. By the end of the study, approximately one-fourth of the patients in each group were receiving hydrochlorothiazide. Both treatment regimens substantially reduced BP to 139/79 mm Hg in the valsartan group and to 137/78 mm Hg in the amlodipine group (Po0.0001 for difference between groups in reduction from baseline), with initial larger differences in BP level between groups. 34 In spite of the differences in BP reduction, the primary composite outcome (cardiac morbidity and mortality) was not significantly different between treatments (hazard ratio ¼ 1.04; 95% CI, 0.94-1.15; P ¼ 0.49).
Results from VALUE on the BP-dependent effects of therapy showed that patients whose BP was controlled at o140/90 mm Hg had fewer CVD events than patients whose BP remained uncontrolled, 35 adding to the large body of data on the overriding importance of intensive BP control, particularly systolic BP, for preventing cardiovascular events. 11, 21, 36 Moreover, 79% of the excess of MIs in the valsartan group occurred during the first 2 years of the VALUE study, when differences in BP between the amlodipine and valsartan groups were greatest. 34 Regardless, the incidence of new-onset diabetes was significantly less with valsartan than with amlodipine (odds ratio ¼ 0.77; 95% CI, 0.69-0.86; Po0.0001). 34 After adjustment for age, history of coronary artery disease and LVH, the incidence of at least one occurrence of atrial fibrillation (odds ratio ¼ 0.84; 95% CI, 0.708-0.998; P ¼ 0.047) and of persistent atrial fibrillation (odds ratio ¼ 0.681; 95% CI, 0.521-0.889; P ¼ 0.005) was lower in the valsartan group. 37 The Jikei Heart Study randomized 3081 Japanese patients aged 20-79 years to either valsartan 40-160 mg day À1 or other antihypertensive treatment not involving ARBs. 38 After a median of 3.1 years, there was no difference between the two treatment groups in achieved diastolic or systolic BP; however, the relative risk of the composite primary end point 4 6 0 5 4 5 2 4 4 4 6 0 4 3 9 2 4 3 1 2 4 2 4 7 4 1 8 9 4 1 1 2 4 0 4 7 3 8 9 7 1 8 8 9 9 0 1 4 5 8 8 4 4 9 4 4 4 1 4 4 3 4 9 4 2 8 9 4 2 0 5 4 1 3 5 4 0 6 6 3 9 9 2 3 8 2 1 1 8 5 4 8 7 
18
(cardiovascular morbidity and mortality) was reduced by 39% (95% CI, 21-53%; P ¼ 0.0002) in patients receiving valsartan. The reduction in risk was attributable primarily to a lower incidence of stroke, angina pectoris and heart failure. Mortality did not differ between the treatment groups.
38
Evidence from mega-trials of DHP-CCBs The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), the largest (n433 000) double-blind treatment trial of hypertension, compared the efficacy of different initial antihypertensive regimens in terms of protection from coronary heart disease. 24 Mean BP at randomization was 146/84 mm Hg across treatments; 90% patients had received previous treatment. Overall, initial allocation to amlodipine 2.5-10 mg or lisinopril 10-40 mg was shown to provide a level of risk reduction comparable to that seen with a thiazide like diuretic (chlorthalidone 12.5-25 mg) in terms of fatal coronary heart disease or nonfatal MI and all-cause mortality. 24 Approximately 40% patients were receiving open-label add-on treatment (atenolol, clonidine or reserpine) at 5 years. 24 In the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), amlodipine-based antihypertensive therapy (5-10 mg) was more effective than atenolol-based therapy (50-100 mg) in preventing CVD in high-risk hypertensive patients (n419 000). 19 Mean BP at baseline was roughly 164/94 mm Hg in both treatment groups. After a median 5.5 years of follow-up, the amlodipine group (of whom a majority were also receiving therapy with perindopril 4-8 mg) had fewer primary events (nonfatal MI and fatal coronary heart disease) than the atenolol group (of whom a majority were also receiving therapy with bendroflumethiazide 1.25-2.5 mg). The difference in events was not statistically significant (429 vs 474; unadjusted hazard ratio ¼ 0.90; 95% CI, 0.79-1.02; P ¼ 0.10), 19 as the study was stopped early because of significant mortality and stroke benefits favouring the amlodipine group, and the necessary number of primary end points was not reached. The amlodipine group also had a significantly lower incidence of new-onset diabetes compared with the atenolol group (567 vs 799; hazard ratio ¼ 0.70; 95% CI, 0.63-0.78; Po0.0001). Other secondary end points, including fatal and nonfatal stroke, total cardiovascular events and all-cause mortality, also favoured the amlodipine-based therapy (Figure 3) . Overall, BP changes favoured amlodipine by 2.7/1.9 mm Hg in the trial, but did not explain more than a part of the difference in outcomes. 19, 39 In a substudy of ASCOT, the Conduit Artery Function Evaluation (CAFE) study, the amlodipine-based regimen significantly reduced central aortic pressure compared with the atenolol-based regimen, despite similar reductions in brachial systolic BP. 40 This finding was suggested by the authors as a possible mechanism for the difference in outcomes between the treatment arms in ASCOT, as central aortic pulse pressure may be a key determinant of clinical outcomes in patients with hypertension. 40 The Comparison of Amlodipine vs Enalapril to Limit Occurrences of Thrombosis (CAMELOT) study also provides evidence that treatment with a long-acting DHP-CCB is associated with clinical benefits in patients with coronary artery disease who have relatively normal or borderline elevated BP, with or without prior antihypertensive treatment. 41 Enrolment in the CAMELOT study was restricted to coronary artery disease patients whose baseline BP (treated or untreated) was considerably lower than 140/90 mm Hg (baseline average, B130/ 78 mm Hg). 41 Patients were randomized to amlodipine 10 mg, enalapril 20 mg or placebo. Approximately 60% patients had a history of hypertension, and BP was significantly reduced by both active treatments compared with placebo (by 5/3 mm Hg in the amlodipine group and 5/2 mm Hg in the enalapril group). This reduction in BP was associated with a 31% relative reduction in cardiovascular events in the amlodipine group (95% CI, 12-46%; P ¼ 0.003) and a 15% relative reduction in the enalapril group (95% CI, À7 to 33%; P ¼ 0.16) compared with placebo. 41 A CAMELOT substudy using intravascular ultrasound showed a trend toward less progression of atherosclerosis with amlodipine compared with placebo, whereas there was no difference between enalapril and placebo. 41 Evidence from ACEI/DHP-CCB studies The combination of an ACEI plus amlodipine is well known. 19, 42, 43 The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) study 44, 45 is the first trial designed to compare initial antihypertensive therapy with two different combination regimens on major cardiovascular end points in patients with high-risk hypertension. Preliminary results were announced at the American College of Cardiology in March 2008. The trial randomized 11 400 hypertensive men and women X55 years of age with evidence of CVD, renal disease or target organ damage to one out of two fixed-dose combinations: amlodipine/benazepril 5-10/40 mg day À1 or benazepril/hydrochlorothiazide 40/12.5-25 mg day
À1
. Both regimens lowered BP effectively, with more than 75% subjects in both treatment groups achieving levels o140/90 mm Hg. However, the risk of the primary end point (CVD death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina pectoris or revascularization procedures) was reduced by 20% in the benazepril/amlodipine group compared with the benazepril/hydrochlorothiazide group (hazard ratio ¼ 0.80; 95% CI, 0.71-0.90). 46 Evidence from ARB/DHP-CCB studies Although ARBs and ACEIs have comparable BP-lowering efficacy, ARBs provide effective RAS blockade with greater tolerability. The cough and angioedema associated with ACEIs do not occur with ARBs, although ARBs should be prescribed cautiously in patients with a history of ACEIinduced angioedema. 16, 17, 47 The efficacy and tolerability of ARB/DHP-CCB combination therapy has been demonstrated in a number of studies. In two double-blind, randomized, placebo-controlled trials, the combination of valsartan and amlodipine reduced BP to a greater extent than monotherapy with either agent, was associated with BP control rates 480% and was equally more effective across subgroups of patients (younger vs older, white vs African-American). 48, 49 In another study, combination therapy, administered once daily, of amlodipine (5-10 mg) plus valsartan 160 mg was as effective as lisinopril (10-20 mg) plus hydrochlorothiazide 12.5 mg in patients with stage 2 hypertension, lowering BP by equivalent amounts (35.8/ 28.6 mm Hg and 31.8/27.6 mm Hg, respectively; for both, Po0.001 vs baseline) and resulting in similar BP control rates (o140/90 mm Hg; 67.2 and 56.1%, respectively). 50 In a recently reported trial of 1940 patients with mild-to-severe hypertension (diastolic BP X95 and p120 mm Hg), combinations of amlodipine 5-10 mg day À1 plus olmesartan 10-40 mg day À1 for 8 weeks were associated with significantly greater reductions in BP compared with amlodipine or olmesartan alone (Po0.0001 for all comparisons). 51 Reductions in mean systolic BP/diastolic BP were À30.1/À19.0 mm Hg with amlodipine 10 mg plus olmesartan 40 mg, compared with À4.8/À3.1 mm Hg with placebo and À19.7/À12.7 mm Hg with amlodipine 10 mg monotherapy.
Evidence of effects beyond BP control with RAS inhibitor/CCB combination therapy Whether these outcome trials provide evidence of particular benefits of RAS-blocking agents and DHPCCBs beyond BP control has been a matter of intense debate, in part because many trials, such as ALLHAT and VALUE, did not achieve equivalent BP reductions among treatment arms. 11, 20, 24, 34 Importantly, LIFE was the first end-point trial in patients with hypertension to show a divergent therapeutic outcome for one treatment modality over another with equivalent BP control. 35 More recently, the Jikei Heart Study also reported improved outcomes with RAS blockade despite equivalent BP control. 38 A preferential effect of RAS blockade in improving indices of LVH has been postulated as a potential mechanism to explain these beneficial results. 21, 52 Electrocardiographically or echocardiographically documented LVH is associated with increased cardiovascular risk in patients with hypertension, with the risk of CVD events increasing by as much as two-to fivefold. 21, 52 In the LIFE study, left ventricular mass was reduced to a greater extent with losartan than with atenolol, despite similar BP reductions and a similar distribution of add-on antihypertensive medications. 18, 52 Moreover, a clear-cut gradient of risk was observed, such that greater the decrease in the left ventricular mass as assessed by yearly electrocardiogram, greater the reduction in major CVD events. 53 This effect was seen at systolic BP levels in the borderline-high range based on current guidelines. 18 Rationale for antihypertensive therapy with RAS inhibitor/DHP-CCB combination
The majority of hypertensive patients need at least two drugs to adequately lower elevated BP and achieve the intensive BP targets recommended in national and international guidelines. 1, 14 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommends that clinicians consider initiating therapy with two drugs-either as separate agents or as a fixed-dose combination-when BP is X20/10 mm Hg above the target;
1 the European Society of Hypertension/ European Society of Cardiology guidelines suggest that low-dose combination therapy be considered for first-step treatment when BP is X160/100 mm Hg or total cardiovascular risk is high or very high. 14 Low-dose combination therapy is usually more effective than monotherapy with higher doses of either component agent. 20 Fixed-dose combination formulations also simplify treatment regimens, which may improve adherence with therapy. 54, 55 Combination therapy to lower BP is an important treatment strategy in patients with high-risk conditions, such as diabetes, chronic kidney disease or subclinical target organ damage, and in patients with higher pretreatment BP. 1, 14 In fact, most large, randomized clinical hypertension trials have used combination therapy to ensure robust BP control and thereby optimize clinical outcomes. 14 As with choosing a drug for initial monotherapy, the choice of which combination of agents to use depends on a number of patient factors. These include the overall cardiovascular risk profile, the presence of target organ damage or other co-existing disorders that either favour or limit the use of particular drug classes, and the possibility of interactions with drugs used by the patient for other conditions.
14 The JNC 7 guidelines recommend using diuretics as a component of combination therapy for most patients, 1 as these agents enhance the BP-lowering efficacy of all other antihypertensive classes, but this strategy has now been challenged with the recent ACCOMPLISH data. The JNC 7 and European guidelines recommend that hypertensive patients with diabetes mellitus or chronic kidney disease receive treatment that includes an ACEI or ARB, 1, 14 and the European guidelines further recommend use of these RASblocking agents in patients with the metabolic syndrome or at high risk for the development of diabetes.
14 The combination of an RAS blocker with a diuretic has advantages related to their complementary mechanisms of action-diuretics deplete serum levels of sodium and potassium, leading to activation of the RAS, whereas ACEIs and ARBs inhibit the RAS and reduce angiotensin-II-mediated sodium retention in the kidney. 54, 56 However, combining a CCB with a RAS blocker may offer enhanced BP control without the metabolic effects often associated with diuretics. There is also evidence that combining either an ACEI or an ARB with a DHP-CCB may reduce the incidence of ankle oedema, the most common adverse effect of DHPCCBs. [57] [58] [59] Long-acting DHP-CCBs are effective BP-lowering agents across a range of patient groups, including the elderly and African-Americans, and are suitable components of combination therapy with a wide variety of antihypertensive classes. 15, 20 Combining RAS blockade with a long-acting DHP-CCB may provide complementary effects that lead to more global risk-factor reduction 20, 60 and better outcome as shown in the ACCOMPLISH study. Blockade of the RAS provides clear benefits in preventing heart failure and the progression of renal disease in patients with hypertension. 20 The benefits of DHPCCBs in CVD prevention may be related to antioxidative effects that result in antiatherosclerotic properties, 20, 41, 61 a hypothesis that is supported by the results of studies such as CAMELOT. 41, 52 
Future directions and conclusions
In patients with hypertension, LVH is a powerful predictor of CVD morbidity and mortality. Moreover, the vascular stiffening and ventricular remodelling that can occur as a consequence of long-standing hypertension may be an intermediate step in the pathophysiologic pathway between elevated BP and cardiovascular events, whether or not abnormalities in systolic function are present. 62 Indeed, the prevalence of diastolic dysfunction, which itself is an independent predictor of the development of heart failure and cardiac death, may be as high as 90% in hypertensive patients with LVH and as high as 50% in hypertensive individuals in the community. 63, 64 Antihypertensive treatment to achieve aggressive BP control, specifically with a regimen that includes RAS blockade, is a key therapeutic strategy for treating diastolic dysfunction, as hypertrophy and vascular stiffness are associated with the activation of neurohormonal mechanisms mediated by the RAS. 65 Treatment with long-acting DHP-CCBs may also limit the progression and consequences of vascular stiffening, as suggested by the results of the CAFE study discussed earlier. 40 RAS blocker/DHP-CCB combination therapy may therefore provide complementary effects in this patient population. This hypothesis is being studied in the Exforge Aggressive Control of Hypertensive Disease and Evaluation of End Organ Damage (EXCEED) trial, which is evaluating the effect of combination treatment with valsartan plus amlodipine to different systolic BP targets (o130 vs o140 mm Hg) on diastolic properties of myocardium in patients with hypertension and diastolic dysfunction.
In conclusion, the combination of RAS inhibitors with DHP-CCBs may provide more intensive BP control to currently recommended targets and cardiovascular protective effects that lead to more global risk-factor reduction in patients with hypertension. Given their excellent and complementary tolerability profiles, combination therapy with an ARB or ACEI with a long-acting DHP-CCB is a rational choice for patients requiring two or more antihypertensive agents.
